EIF4E and acute myeloid leukemia: In our institution, patients with high eIF4E had significantly shorter 3-year OS than those with low eIF4E in all AML patient cohorts (Figure 6C, p < 0.05) and the de novo cohort (Figure 6D, p < 0.05).